Valvular & structural heart disease
Valvular Heart Disease Associations With Cardiac Biomarkers Using AI-Guided Echocardiography: The RURAL Cohort Study
Authors' conclusion
MVP prevalence aligned with population-based epidemiologic studies. PREVENT risk category may identify individuals at higher risk for MVP and for other VHD.
Study context
- Population
- Rural US South cohort (Risk Underlying Rural Areas Longitudinal study)68.7% women
- Participants
- 2,621 participants
- Outcome
- Prevalence of MVP and other valvular heart disease
Main finding
As reported in the abstract
Prevalence
Mitral valve prolapse (MVP) prevalence
1.9%
Other valvular heart disease prevalence
11.2%
Observational data: associations, not effects.
Further findings
| Outcome | Estimate |
|---|---|
| High-sensitivity cardiac troponin T, MVP vs non-MVPLower in MVP; no difference by MVP severity · subset | 0.64 (95% CI 0.58–0.71) |
| NT-proBNP, severe MVP vs non-MVPHigher in severe MVP · subset | 2.03 (95% CI 1.49–2.78) |
MVP and other valvular heart disease by PREVENT 10-year cardiovascular disease (CVD) risk category (vs low risk)
- Odds of MVP lower and odds of other valvular heart disease higher in borderline and intermediate/high vs low PREVENT risk
Original publication
Valvular Heart Disease Associations With Cardiac Biomarkers Using AI-Guided Echocardiography: The RURAL Cohort Study. JACC Adv. Published 16 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →